Biotech Values

[DewDiligence]

IDIX 2010 Possible/Probable News Flow

[Updated for 1/14/10 JPM webcast.]


HCV

Any day: Start phase-1 trial for IDX320 protease inhibitor. (A CTA, the European equivalent of an IND, was submitted in 4Q09.)

Apr 2010 at EASL: Report additional phase-2a data for IDX184 nucleotide polymerase inhibitor. (Interim data from the 50mg qD cohort were reported on 1/11/10.)

Apr 2010 at EASL: Report additional phase-1 data for IDX375 non-nucleoside polymerase inhibitor. (Interim data were reported on 1/11/10.)

Timing uncertain (likely 1H10): Ink IDX184 partnership.

Mid 2010: Start phase-1/2 PoC study for IDX375.

Mid 2010: Start phase-1/2 PoC study for IDX320.

Nov 2010 at AASLD: Present complete phase-2 data for IDX184.

2H10: Select lead compound for NS5A program. Start phase-1 in 1H11.


HIV

Mar 2010: GSK* completes IDX899 PK/food study testing multiple formulations at 100mg qD (#msg-44790049).

2Q10: Start phase-2b trials of IDX899 in treatment-naïve and treatment-experienced settings using the preferred 100mg formulation from the PK/food study.

*GSK is the operator of ViiV Healthcare, the joint venture with PFE that is the licensee of IDX899 (#msg-43254006).